This review article aims to present the evidence on the association between depression and metabolic diseases, but above all to discuss the relationship between antidepressants and the metabolic risk profile. In addition, the current evidence on antidepressant pharmacotherapy in depressed patients with comorbid obesity, metabolic syndrome and T2DM is presented.
Antidepressants are among the most commonly prescribed drugs in the world. The medication is often and often discontinued without the knowledge of the practitioner. Knowledge of the withdrawal and rebound phenomena that may occur is essential for treatment, prevention and education.